What is the level of liabilities of ImmuPharma this year?
ImmuPharma has a debt balance of 1.45 M GBP this year.
ImmuPharma Liabilities 2024
ImmuPharma Liabilities
1.45 M GBP
ImmuPharma Dividend yield
Ticker
IMM.L
ISIN
GB0033711010
WKN
A0BMC4
In 2024, ImmuPharma's total liabilities amounted to 1.45 M GBP, a -8.39% difference from the 1.58 M GBP total liabilities in the previous year.
ImmuPharma Aktienanalyse
What does ImmuPharma do?
ImmuPharma PLC is a biopharmaceutical company specializing in the development of drugs for the treatment of autoimmune diseases and cancer. The company was founded in 1999 and is headquartered in London, England. ImmuPharma's history began with the discovery of a new peptide extracted from the trail of a snail. This substance has potent immunomodulatory potential and can inhibit the growth of certain tumor cells. ImmuPharma recognized the potential of this discovery and began developing a new drug based on this peptide. ImmuPharma's business model is to develop innovative drugs and license or sell them to large pharmaceutical companies. The company works closely with leading scientists and experts in drug development to ensure the efficacy and safety of its products. ImmuPharma has focused on two main areas: autoimmune diseases and cancer. Autoimmune diseases are conditions in which the immune system malfunctions and attacks the body. The autoimmune diseases that ImmuPharma targets include lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and myasthenia gravis. ImmuPharma has also developed a drug called Lupuzor for the treatment of systemic lupus erythematosus (SLE). SLE is a severe autoimmune disease that causes inflammation and pain in various parts of the body. Lupuzor was developed as a first-in-class drug that regulates the immune system and reduces inflammation without compromising the body's normal defense function. In the field of cancer, ImmuPharma has also developed promising products that aim to inhibit tumor progression. The company has identified and tested a range of peptide- and protein-based drug candidates, including IPP-204106, which is used for the treatment of advanced prostate cancer. Last year, ImmuPharma also developed a new drug called Ureka for the treatment of urinary tract infections. Ureka is a bacterial toxin that specifically targets E. coli bacteria, which are the most common cause of urinary tract infections. In recent years, ImmuPharma has entered into several important partnerships to advance the development of its drugs. One partnership is with the Chinese company Avion Pharmaceuticals, which holds the marketing rights for Lupuzor in North America, Australia, and New Zealand. Another partnership is with the US company Orphan Reach, which supports the development and marketing of Ureka. Overall, ImmuPharma represents innovation and progress in drug development. The company is dedicated to a crucial purpose, seeking cures for those suffering from autoimmune diseases and cancer. Through a combination of scientific excellence and strategic partnerships, ImmuPharma has the potential to achieve significant therapeutic advancements and improve the lives of countless patients. ImmuPharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing ImmuPharma's Liabilities
ImmuPharma's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating ImmuPharma's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing ImmuPharma's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
ImmuPharma's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in ImmuPharma’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about ImmuPharma Stock
What were the liabilities of ImmuPharma compared to the previous year?
The liabilities of ImmuPharma have increased by -8.39% dropped compared to the previous year.
What are the consequences of high debt for investors of ImmuPharma?
High liabilities can pose a risk for investors of ImmuPharma, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in ImmuPharma?
Low liabilities mean that ImmuPharma has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of ImmuPharma affect the company?
An increase in liabilities of ImmuPharma can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of ImmuPharma affect the company?
A decrease in the liabilities of ImmuPharma can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of ImmuPharma?
Some factors that can influence the liabilities of ImmuPharma include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of ImmuPharma so important for investors?
The liabilities of ImmuPharma are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can ImmuPharma take to modify the liabilities?
To change its liabilities, ImmuPharma can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does ImmuPharma pay?
Over the past 12 months, ImmuPharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ImmuPharma is expected to pay a dividend of 0 GBP.
What is the dividend yield of ImmuPharma?
The current dividend yield of ImmuPharma is .
When does ImmuPharma pay dividends?
ImmuPharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ImmuPharma?
ImmuPharma paid dividends every year for the past 0 years.
What is the dividend of ImmuPharma?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is ImmuPharma located?
ImmuPharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von ImmuPharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ImmuPharma from 5/30/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 5/30/2024.
When did ImmuPharma pay the last dividend?
The last dividend was paid out on 5/30/2024.
What was the dividend of ImmuPharma in the year 2023?
In the year 2023, ImmuPharma distributed 0 GBP as dividends.
In which currency does ImmuPharma pay out the dividend?
The dividends of ImmuPharma are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von ImmuPharma
Our stock analysis for ImmuPharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImmuPharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
